Effects of growth hormone on testicular dysfunction induced by cyclophosphamide (CP) in GH-deficient rats

Endocrine Journal

Volumn 49, Issue 6, 2002, Pages 611-619

  Satoh, Kazumasa ^a   Ohyama, Kenji ^a   Nakagomi, Yoshiko ^a   Ohta, Masanori ^a   Shimura, Yoshie ^a   Sano, Tomoaki ^a   Ishikawa, Hiromichi ^b   Amemiya, Shin ^a   Nakazawa, Shinpei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b JCR Pharmaceuticals Co   (Japan)

Author keywords

Cyclophosphamide; GH; GH deficiency; Spermatogenesis

Indexed keywords

CYCLOPHOSPHAMIDE; GROWTH HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GONAD FUNCTION; GROWTH HORMONE DEFICIENCY; HISTOPATHOLOGY; LEYDIG CELL; NONHUMAN; RAT; SEXUAL MATURATION; SPERMATOGENESIS; SURVIVAL RATE; TESTIS DISEASE;

ANIMALS; CYCLOPHOSPHAMIDE; GROWTH HORMONE; MALE; MUTAGENS; ORGAN SIZE; RATS; RATS, INBRED LEW; SPERM COUNT; SPERM MOTILITY; SPERMATOCYTES; SPERMATOGENESIS; TESTICULAR DISEASES; TESTIS;

EID: 0036965278     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.49.611     Document Type: Article

References (25)

1. Sheikholislam BM, Stempfel RS (1972) Hereditary isolated somatotropin deficiency: effects of human growth hormone administration. Pediatrics 49: 362-374.
2. Laron Z (1984) Laron-type dwarfism, hereditary somatomedin deficiency. A review. Adv Int Med Paed 51: 117-140.
3. Darendeliler F, Hindmarsh PC, Preece MA, Cox L, Brook CG (1990) Growth hormone increases rate of pubertal maturation. Acta Endocrinol (Copenh) 122: 414-416.
4. Hibi I, Tanaka T, Tanae A, Kagawa J, Hashimoto N, Yoshizawa A, Shizume K (1989) The influence of gonadal function and effect of gonadal suppression treatment on final height in growth hormone (GH)-treated GH-deficient children. J Clin Endocrinol Metab 69: 221-226.
5. Odell WD, Swerdloff RS (1976) Etiologies of sexual maturation: a model system based on the sexually maturing rat. Recent Prog Horm Res 32: 245-288.
6. Chatelain PG, Sanchez P, Saez JM (1991) Growth hormone and insulin-like growth factor I treatment increase testicular lutenizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice. Endocrinology 128: 1857-1862.
7. Ohyama K, Ohta M, Nakagomi Y, Yamori T, Sano T, Shimura Y, Satoh K, Nakazawa M (1995) Effects of growth hormone and insulin-like growth factor I on testosterone secretion in premature male rats. Endocr J 42: 817-820.
8. Ohyama K, Iwatani N, Nakagomi Y, Ohta M, Shimura Y, Sano T, Satoh K, Mabe H, Ishikawa H (1999) Growth hormone advances spermatogenesis in premature rats treated with gonadotropin-releasing hormone agonist. Endocr J 46: 555-562.
9. Breier BH, Vickers MH, Gravance CG, Casey PJ (1996) Growth hormone therapy markedly increases the motility of spermatozoa and concentration of insulin-like growth factor-I in seminal vesicle fluid in the male GH-deficient dwarf rat. Endocrinology 137: 4061-4064.
10. Fairley KF, Barrie JU, Johnson W (1972) Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1: 568-569.
11. Chapman RM (1983) Gonadal injury resulting from chemotherapy. Am J Indust Med 4: 149-161.
12. Matsui H, Mitsumori K, Yasuhara K, Onodera H, Shimo T, Takahashi M (1995) Morphological evaluation of cyclophosphamide testicular toxicity in rat using quantitative morphometry of spermatogenic cycle stages. J Toxicol Sci 20: 407-414.
13. Lu CC, Meistrich ML (1979) Cytotoxic effect of chemotherapeutic drugs on mouse testis cells. Cancer Res 39: 3575-3582.
14. Leblond CP, Clermont Y (1952) Definition of the stages of the cycle of the seminiferous epithelium in the rat. Ann NY Acad Sci 55: 548-573.
15. Takahashi M, Matsui H (1993) Mechanisms of testicular toxicity. J Toxicol Pathol 6: 161-174.
16. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anatomical Record 94: 238-244.
17. Delic JI, Bush C, Peckham MJ (1986) Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. Cancer Res 46: 1909-1914.
18. Delic JI, Harwood JR, Stanley JA (1987) Time dependence for the protective effect of androgen from procarbazine-induced damage to rat spermatogenesis. Cancer Res 47: 1344-1347.
19. Jegou B, Velez de la Calle JF, Bauche F (1991) Protective effect of medroxyprogesterone acetate plus testosterone against radiation-induced damage to the reproductive function of male rats and their offspring. Proc Natl Acad Sci USA 88: 8710-8714.
20. Parchuri N, Wilson G, Meistrich ML (1993) Protection by gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBNF1 hybrid rats. J Androl 14: 257-266.
21. Meistrich ML, Wilson G, Ye W-S, Kurdoglu B, Parchuri N, Terry NHA (1994) Hormonal protection from procarbazine-induced testicular damage is selective for survival and recovery of stem spermatogonia. Cancer Res 54: 1027-1034.
22. Ward JA, Robinson J, Furr BJA, Shalet SM, Morris ID (1990) Protection of spermatogenesis in rats from the cytotoxic procarbazine by depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 50: 568-574.
23. Kangasniemi M, Wilson G, Huhtaniemi I, Meistrich ML (1995) Protection against procarbazine-induced testicular damage by GnRH-agonist and anti-androgen treatment in the rat. Endocrinology 136: 3677-3680.
24. Meistrich ML, Wilson G, Ye W-S, Thrash C, Huhtaniemi I (1996) Relationship among hormonal treatments, supression of spermatogenesis, and testicular protection from chemotherapy-induced damage. Endocrinology 137: 3821-3831.
25. Morris ID, Shalet SM (1990) Protection of gonadal function from cytotoxic chemotherapy and irradiation. Ballieres Clin Endocrinol Metab 4: 97-118.